NAMSW
NewAmsterdam Pharma Company N.V. WarrantKey Statistics
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic diseases, particularly dyslipidemia, which contributes significantly to cardiovascular risks. The firm is harnessing a robust research and development framework to assess its novel drug candidates, aiming for regulatory approvals that can catalyze growth. By targeting substantial unmet medical needs in this critical area, NewAmsterdam Pharma is positioned to improve patient outcomes while delivering sustained value to its shareholders, making it an attractive prospect for institutional investors navigating the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $22.57M |
| Gross Profit (TTM) | $22.57M |
| EBITDA | $-214.95M |
| Operating Margin | -1922.00% |
| Return on Equity | -29.50% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.70 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | 0 |
| Float | $80.70M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NAMSW and any ticker you trade — then tracks every position and per-strategy win rate.